Stay updated with breaking news from Time We Know. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In July 2020, almost a year before Biogen's dementia medication Aduhelm was approved, the company convened a meeting of advocates and experts to discuss "strategies to help communities of color address dementia."
Do We All Have Alzheimerâs? Drug Makers Might Want You to Think So July 30, 2021 From The Baltimore Sun: “This month, the Food and Drug Administration changed the label for the recently approved Alzheimerâs treatment aducanumab â sold under the brand name ‘Aduhelm’ â to specify that the controversial drug made by U.S. biotech company Biogen should be used only by patients with mild dementia or mild cognitive impairment. This should be no bar to widespread use, however, as recent efforts indicate that Biogen may be trying to persuade adults who occasionally mispla...